Red cell transfusion and alloimmunization in sickle cell disease.

Content Provider	Europe PMC
Author	Linder, Grace E. Chou, Stella T.
Abstract	Red cell transfusion remains a critical component of care for acute and chronic complications of sickle cell disease. Randomized clinical trials demonstrated the benefits of transfusion therapy for prevention of primary and secondary strokes and postoperative acute chest syndrome. Transfusion for splenic sequestration, acute chest syndrome, and acute stroke are guided by expert consensus recommendations. Despite overall improvements in blood inventory safety, adverse effects of transfusion are prevalent among patients with sickle cell disease and include alloimmunization, acute and delayed hemolytic transfusion reactions, and iron overload. Judicious use of red cell transfusions, optimization of red cell antigen matching, and the use of erythrocytapheresis and iron chelation can minimize adverse effects. Early recognition and management of hemolytic transfusion reactions can avert poor clinical outcomes. In this review, we discuss transfusion methods, indications, and complications in sickle cell disease with an emphasis on alloimmunization.
Page Count	11
ISSN	03906078
Journal	Haematologica
Volume Number	106
PubMed Central reference number	PMC8252926
Issue Number	7
PubMed reference number	33792218
e-ISSN	15928721
DOI	10.3324/haematol.2020.270546
Language	English
Publisher	Fondazione Ferrata Storti
Publisher Date	2021-07-01
Access Restriction	Open
Rights License	This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. Copyright© 2021 Ferrata Storti Foundation
Content Type	Text
Resource Type	Article
Subject	Hematology